沙格列汀联合甘精胰岛素治疗老年2型糖尿病的有效性和安全性研究  

The effectiveness and safety of saxagliptin combined with insulin glargine in the treatment of gerontal patients with type 2 diabetes mellitus

作　　者：高静[1] 李新岩[1] 王敏哲[1] 

机构地区：[1]新疆医科大学第五附属医院内分泌科,乌鲁木齐830011

出　　处：《中国医学前沿杂志（电子版）》2015年第8期29-31,共3页Chinese Journal of the Frontiers of Medical Science(Electronic Version)

基　　金：新疆医科大学科创基金(XJC2012113)

摘　　要：目的 观察沙格列汀联合甘精胰岛素治疗老年2 型糖尿病的有效性和安全性.方法 将60 例年龄≥ 60 岁、糖化血红蛋白（HbA1c）为8% ～ 11%、单独使用甘精胰岛素或联合口服二甲双胍血糖控制欠佳的老年2 型糖尿病患者随机分为观察组和对照组.观察组患者给予沙格列汀＋甘精胰岛素（Sax ＋ Gla）治疗,对照组患者给予阿卡波糖＋甘精胰岛素（Aca ＋ Gla）治疗,观察两组患者治疗前后空腹血糖（FBG）、餐后2 小时血糖（2hBG）、HbA1c、胰岛素用量及不良反应发生情况.结果 治疗后24 周,两组患者FBG、2hBG、HbA1c 水平均较基线水平降低（P 〈 0.05）,低血糖和其他不良反应发生率比较均无显著差异（P 〉 0.05）.观察组患者胰岛素用量和体重增加明显低于对照组（P 〈 0.05）.结论 沙格列汀联合甘精胰岛素可明显改善老年2 型糖尿病患者的血糖水平,且具有较好的安全性.Objective To observe the effectiveness and safety of saxagliptin combined with insulin glargine in the treatment of gerontal patients with type 2 diabetes mellitus. Method 60 gerontal patients who were injected insulin glargine or combined with metformin and whose blood glucose were poor controled with Hb A1 c 8% ~ 11%, were divided into treatment group and control group. Treatment group patients were received saxagliptin combined with insulin glargine(Sax + Gla), control group were received acarbose combined with insulin glargine(Aca + Gla). FBG, 2h BG, Hb A1 c, insulin dose, adverse reaction were compared before and after the treatment between the two groups. Result 24 weeeks after the treatment, FBG、2h BG、Hb A1 c of the two groups decreased significantly(P < 0.05). The incidence of hypoglycemia and other adverse effects were similar(P > 0.05). The insulin dose and weight increase in treatment group were lower than control group(P < 0.05). Conclusion Saxagliptin combined with insulin glargine is effective and safe for gerontal patients with type 2 diabetes mellitus.

关 键 词：沙格列汀 2型糖尿病 老年患者 有效性 安全性 

分 类 号：R587.1[医药卫生—内分泌]